The Immunotherapy Trials in Gastroesophageal Carcinomas

The Immunotherapy Trials in Gastroesophageal Carcinomas

moasc

2 years
428 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Farshid Dayyani, MD, PhD of UC Irvine Health discusses the Immunotherapy Trials, the Keynote trial and the Checkmate trial, at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.
Up Next Autoplay
Personalized Algorithms: How is this different?
Personalized Algorithms: How is this different?
Category: Immunotherapy
2 Views
Cancer-News 19 hours
Algorithm Personalizing Best Targets for Immunotherapy
Algorithm Personalizing Best Targets for Immunotherapy
Category: Immunotherapy
2 Views
Cancer-News 20 hours
Algorithm personalizes the best targets for immunotherapy for cancer mutations.
Algorithm personalizes the best targets for immunotherapy for cancer mutations.
Category: Immunotherapy
5 Views
Cancer-News 20 hours
Analysis of Patients with Prior Gastrectomy Treated with LONSURF® (trifluridine and tipiracil) Published in JAMA Oncology
Analysis of Patients with Prior Gastrectomy Treated with LONSURF® (trifluridine and tipiracil) Published in JAMA Oncology
Category: Pancreatic Cancer
3 Views
Cancer-News 21 hours
Phase 2 PLEIADES Study: How This Affects Clinicians?
Phase 2 PLEIADES Study: How This Affects Clinicians?
Category: Multiple Myeloma
0 Views
Mount Sinai Health System 22 hours
PLEIADES Study: How Long Are Patients in Clinic?
PLEIADES Study: How Long Are Patients in Clinic?
Category: Multiple Myeloma
0 Views
Mount Sinai Health System 22 hours
Phase 2 PLEIADES Study
Phase 2 PLEIADES Study
Category: Multiple Myeloma
0 Views
Mount Sinai Health System 23 hours
BEACON Trial: What's Next?
BEACON Trial: What's Next?
Category: Colorectal Cancer
2 Views
Cancer-News 1 day
Phase 3 BEACON CRC Trial
Phase 3 BEACON CRC Trial
Category: Colorectal Cancer
15 Views
Cancer-News 1 day
EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19
EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19
Category: Bladder Cancer
9 Views
Cancer-News 1 day